Upgrade to SI Premium - Free Trial

Immuneering Corporation (IMRX)

3.74 +0.01 (0.27%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) October 2, 2026 9:00 AM - StreetInsider Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer September 28, 2026 7:30 AM - StreetInsider Immuneering to Present at the ESMO Congress 2026 September 24, 2026 7:30 AM - StreetInsider Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival September 10, 2026 7:30 AM - StreetInsider Immuneering to Participate in Upcoming Investor Conferences September 3, 2026 4:05 PM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Immuneering Corporation (IMRX) August 27, 2026 7:08 AM - StreetInsider Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug August 26, 2026 5:16 PM - StreetInsider Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients August 26, 2026 5:16 PM - Globe NewsWire H.C. Wainwright Starts Immuneering Corporation (IMRX) at Buy August 6, 2026 6:06 AM - StreetInsider Immuneering Corporation (IMRX) Reports In-Line Q2 EPS August 5, 2026 9:09 AM - StreetInsider Form 10-Q Immuneering Corp For: Jun 30 August 5, 2026 7:57 AM - SEC Filing Form 8-K Immuneering Corp For: Aug 05 August 5, 2026 7:41 AM - SEC Filing Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates August 5, 2026 7:30 AM - StreetInsider Form SCHEDULE 13G Immuneering Corp Filed by: BlackRock, Inc. July 28, 2026 4:46 PM - SEC Filing Full Article List